Who are Day One Biopharmaceuticals's investors?

Day One Biopharmaceuticals's investors include Access Biotechnology, Atlas Venture, Canaan Partners, Access Industries, RA Capital, The Column Group.

How much funding has Day One Biopharmaceuticals raised?

Day One Biopharmaceuticals has disclosed $130M raised across 1 of its 2 known rounds.

Where is Day One Biopharmaceuticals headquartered?

Day One Biopharmaceuticals is headquartered in South San Francisco, US.

Day One Biopharmaceuticals

South San Francisco, US · Founded 2018 · 234 employees on LinkedIn · 6 known investors

Find your way into Day One Biopharmaceuticals

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

Biotech Healthtech

Founders & leadership

Jeremy BenderNamed on SEC filing

Board

Michael Gladstone Board directorPartner at Atlas Venture

Derek DiRocco Board directorPartner at RA Capital

Julie Papanek Grant Co-Founder and Chief Executive Officer2018–2020General Partner at Canaan Partners

John Josey Board directorPartner at The Column Group

Daniel BeckerBoard director

Natalie HollesDirector2021–2026Director at Renasant Bio

Investors · 6

Access Biotechnologylisted by Access BiotechnologyNew York

How we know: Access Biotechnology's portfolio page · funding news · Not right? Tell us

Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · the VCSheet dataset · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · Not right? Tell us

Access IndustriesreportedNew York

How we know: a partner's Signal profile · Not right? Tell us

RA CapitalinferredBostonvia Derek DiRocco · board

How we know: board seat on SEC Form D · Not right? Tell us

The Column GroupinferredSan Francisco · $30Mvia John Josey · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$130M disclosed across 1 of 2 rounds · 2021–2024

▶$130MraisedFeb 2021 · 24 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Jeremy BenderExecutive Officer, Director
Michael GladstoneDirector
Derek DiRoccoDirector
Julie Papanek GrantDirector
John JoseyDirector
Natalie HollesDirector
Daniel BeckerDirector

Offering amount: $130M
Amount sold: $130M
First sale: Feb 2021
Incorporated: Limited Liability Company, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Day One Biopharmaceuticals do?: Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Who are Day One Biopharmaceuticals's investors?: Day One Biopharmaceuticals's investors include Access Biotechnology, Atlas Venture, Canaan Partners, Access Industries, RA Capital, The Column Group.
How much funding has Day One Biopharmaceuticals raised?: Day One Biopharmaceuticals has disclosed $130M raised across 1 of its 2 known rounds.
Where is Day One Biopharmaceuticals headquartered?: Day One Biopharmaceuticals is headquartered in South San Francisco, US.